The Baker Institute is committed to scientific excellence and our ‘2021 Best of Baker Awards’ recognise outstanding research achievement based on scientific publications. They demonstrate areas where scientific discoveries are likely to have significant impact in health and medical research.
Our focus now is on translating this research to develop new drugs and devices, to inform policy, to develop best-practice prevention and treatment guidelines, and to facilitate education programs for healthcare professionals.
This is how our research is making a difference to the health of Australians, and people around the world.
Winners
- Alarmin-activated B cells accelerate murine atherosclerosis after myocardial infarction via plasma cell-immunoglobulin-dependent mechanisms (Basic Science)
- Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings (Clinical/Epidemiology)
Runners up
- Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial (Basic Science)
- Oxygen pathway limitations in patients with chronic thromboembolic pulmonary hypertension (Clinical/Epidemiology)
Other awardees
- Proteomic dissection of large extracellular vesicle surfaceome unravels interactive surface platform (Basic Science)
- A DARPin targeting activated Mac-1 is a novel diagnostic tool and potential anti-inflammatory agent in myocarditis, sepsis and myocardial infarction (Basic Science)
- Deletion of Trim28 in committed adipocytes promotes obesity but preserves glucose tolerance (Basic Science)
- Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases (Basic Science)
- Strain-guided management of potentially cardiotoxic cancer therapy (Clinical/Epidemiology)
- The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation (Clinical/Epidemiology)
- Frequency of interruptions to sitting time: benefits for postprandial metabolism in type 2 diabetes (Clinical/Epidemiology)
- Projecting the incidence of type 2 diabetes-related end-stage kidney disease until 2040: a comparison between the effects of diabetes prevention and the effects of diabetes treatment (Clinical/Epidemiology)